Evidence map›Paper›PMID 35643466›Full record

ArticleRespiratory research2022

Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study.

Jelle R Miedema, Catharina C Moor, Marcel Veltkamp, Sara Baart, Natascha S L Lie, Jan C Grutters, Marlies S Wijsenbeek, Rémy L M Mostard

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jelle R MiedemaDepartment of Pulmonology, Center of Excellence for Interstitial Lung Disease and Sarcoidosis, Erasmus University Medical Center, Rotterdam, The Netherlands. j.miedema@erasmusmc.nl.
Catharina C MoorDepartment of Pulmonology, Center of Excellence for Interstitial Lung Disease and Sarcoidosis, Erasmus University Medical Center, Rotterdam, The Netherlands.
Marcel VeltkampDepartment of Pulmonology, ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands.
Sara BaartDepartment of Biostatistics, Erasmus MC, Rotterdam, The Netherlands.
Natascha S L LieDepartment of Pulmonology, Zuyderland Medical Center, Heerlen, Sittard, The Netherlands.
Jan C GruttersDepartment of Pulmonology, ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands.
Marlies S WijsenbeekDepartment of Pulmonology, Center of Excellence for Interstitial Lung Disease and Sarcoidosis, Erasmus University Medical Center, Rotterdam, The Netherlands.
Rémy L M MostardDepartment of Pulmonology, Zuyderland Medical Center, Heerlen, Sittard, The Netherlands.
Erasmus MC · NLUniversity Medical Center Utrecht · NLZuyderland Medisch Centrum · NLErasmus University Rotterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPirfenidone slows down disease progression in idiopathic pulmonary fibrosis (IPF). Recent studies suggest a treatment effect in progressive pulmonary fibrosis other than IPF. However, the safety and effectiveness of pirfenidone in asbestosis patients remain unclear. In this study, we aimed to investigate the safety, tolerability and efficacy of pirfenidone in asbestosis patients with a progressive phenotype.

methodsThis was a multicenter prospective study in asbestosis patients with progressive lung function decline. After a 12-week observational period, patients were treated with pirfenidone 801 mg three times a day. Symptoms and adverse events were evaluated weekly and patients completed online patient-reported outcomes measures. At baseline, start of therapy, 12 and 24 weeks, in hospital measurement of lung function and a 6 min walking test were performed. Additionally, patients performed daily home spirometry measurements.

resultsIn total, 10 patients were included of whom 6 patients (66.7%) experienced any adverse events during the study period. Most frequently reported adverse events were fatigue, rash, anorexia and cough, which mostly occurred intermittently and were reported as not very bothersome. No significant changes in hospital pulmonary function (forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), 6 min walking test or patient-reported outcomes measures before and after start of pirfenidone were found. Home spirometry demonstrated a FVC decline in 12 weeks before start of pirfenidone, while FVC did not decline during the 24 week treatment phase, but this difference was not statistically significant.

conclusionsTreatment with pirfenidone in asbestosis has an acceptable safety and tolerability profile and home spirometry data suggest this antifibrotic treatment might attenuate FVC decline in progressive asbestosis. Trial registration MEC-2018-1392; EudraCT number: 2018-001781-41.

Indexed as

AsbestosisIdiopathic Pulmonary FibrosisHumansProspective StudiesPyridonesTreatment OutcomepirfenidonePyridonesAnti-fibrotic treatmentAsbestosisEfficacyHome monitoringPirfenidoneSafety

Identifiers

PMID35643466
PMCPMC9148498
OpenAlexW4281785693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.